NZ738480A - Factor xi antibodies and methods of use - Google Patents

Factor xi antibodies and methods of use

Info

Publication number
NZ738480A
NZ738480A NZ738480A NZ73848016A NZ738480A NZ 738480 A NZ738480 A NZ 738480A NZ 738480 A NZ738480 A NZ 738480A NZ 73848016 A NZ73848016 A NZ 73848016A NZ 738480 A NZ738480 A NZ 738480A
Authority
NZ
New Zealand
Prior art keywords
seq
variable region
chain variable
heavy chain
light chain
Prior art date
Application number
NZ738480A
Other versions
NZ738480B2 (en
Inventor
Jorg Eder
Stefan Ewert
Ulrich Hassiepen
Yasser Khder
Lorenz M Mayr
Samu Melkko
Nikolaus Schiering
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to NZ777273A priority Critical patent/NZ777273B2/en
Publication of NZ738480A publication Critical patent/NZ738480A/en
Publication of NZ738480B2 publication Critical patent/NZ738480B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (”Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.

Claims (20)

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:
1. An ed anti-Factor XI (FXI) and/or anti-activated FXI (FXIa) antibody or antigenbinding fragment thereof that binds within the catalytic domain of FXI and/or FXIa wherein the antibody or fragment thereof comprises: (a) a heavy chain variable region CDR1 of SEQ ID NO: 23; a heavy chain variable region CDR2 of SEQ ID NO: 24; a heavy chain variable region CDR3 of SEQ ID NO: 25; a light chain variable region CDR1 of SEQ ID NO: 33; a light chain variable region CDR2 of SEQ ID NO: 34; and a light chain variable region CDR3 of SEQ ID NO: 35; (b) a heavy chain le region CDR1 of SEQ ID NO: 26; a heavy chain variable region CDR2 of SEQ ID NO: 27; a heavy chain variable region CDR3 of SEQ ID NO: 28; a light chain variable region CDR1 of SEQ ID NO: 36; a light chain variable region CDR2 of SEQ ID NO: 37; and a light chain variable region CDR3 of SEQ ID NO: 38; (c) a heavy chain variable region CDR1 of SEQ ID NO: 43; a heavy chain le region CDR2 of SEQ ID NO: 44; a heavy chain variable region CDR3 of SEQ ID NO: 45; a light chain variable region CDR1 of SEQ ID NO: 47; a light chain variable region CDR2 of SEQ ID NO: 37; and a light chain variable region CDR3 of SEQ ID NO: 15; or (d) a heavy chain variable region CDR1 of SEQ ID NO: 46; a heavy chain variable region CDR2 of SEQ ID NO: 4; a heavy chain variable region CDR3 of SEQ ID NO: 5; a light chain variable region CDR1 of SEQ ID NO: 33; a light chain variable region CDR2 of SEQ ID NO: 14; and a light chain variable region CDR3 of SEQ ID NO: 15.
2. The isolated dy or antigen-binding fragment f of claim 1, wherein the antibody or antigen-binding fragment thereof comprises a VH selected from the group consisting of SEQ ID NOs: 9 and 29; and a VL selected from the group consisting of SEQ ID NOs: 19 and
3. The isolated antibody or n-binding fragment thereof of claim 1, n the antibody or antigen-binding fragment thereof comprises a heavy chain comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of SEQ ID NO: 31 and a light chain comprising an amino acid ce that is at least 90% identical to the amino acid sequence of SEQ ID NO: 41.
4. The isolated antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain comprising an amino acid sequence that is at least 95% cal to the amino acid sequence of SEQ ID NO: 31 and a light chain comprising an amino acid sequence that is at least 95% cal to the amino acid sequence of SEQ ID NO: 41.
5. An isolated antibody that specifically binds human FXI and/or FXIa, wherein said antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 31 and a light chain comprising the amino acid ce of SEQ ID NO: 41.
6. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of any one of claims 1-5 and a ceutically acceptable carrier.
7. Use of the dy or antigen-binding fragment thereof ing to any one of claims 1-5 in the manufacture of a medicament for treating a thromboembolic disorder in a subject afflicted with a thromboembolic disorder.
8. The use of claim 7, wherein the subject is afflicted with one or more of ischemic stroke associated with atrial fibrillation and deep vein thrombosis.
9. The use of claim 7, wherein the subject is afflicted with ischemic stroke associated with atrial fibrillation.
10. Use of the antibody or antigen-binding fragment thereof according to any one of claims 1-5 in combination with one or more statin therapies in the manufacture of a medicament for treating a thromboembolic disorder in a subject afflicted with a thromboembolic disorder.
11. A medicament comprising the antibody or antigen-binding fragment thereof ing to any one of claims 1-5.
12. A nucleic acid ng for one or more of the antibodies or antigen-binding fragments f according to any one of claims 1-5.
13. A vector comprising the nucleic acid according to claim 12.
14. A host cell comprising the vector of claim 13, provided that if the cell is a human cell it is ex vivo.
15. Use of the pharmaceutical composition ing to claim 6 in the manufacture of a medicament for treating a thromboembolic disorder in a subject afflicted with a thromboembolic disorder.
16. The use according to claim 15, wherein the subject is afflicted with ischemic stroke associated with atrial fibrillation.
17. The use according to claim 15, wherein the subject is afflicted with deep vein thrombosis.
18. The use according to claim 15, wherein the medicament is to be administered with one or more statin therapies.
19. The isolated antibody or antigen-binding fragment thereof of claim 1, substantially as herein described with reference to any one of the es and/or s thereof.
20. The isolated antibody of claim 5, substantially as herein described with reference to any one of the examples and/or
NZ738480A 2016-06-24 Factor xi antibodies and methods of use NZ738480B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ777273A NZ777273B2 (en) 2016-06-24 Factor XI antibodies and methods of use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562184955P 2015-06-26 2015-06-26
US201662341568P 2016-05-25 2016-05-25
PCT/IB2016/053790 WO2016207858A1 (en) 2015-06-26 2016-06-24 Factor xi antibodies and methods of use

Publications (2)

Publication Number Publication Date
NZ738480A true NZ738480A (en) 2025-03-28
NZ738480B2 NZ738480B2 (en) 2025-07-01

Family

ID=

Also Published As

Publication number Publication date
TW202222839A (en) 2022-06-16
ZA201708589B (en) 2018-11-28
AU2019264514A1 (en) 2019-12-05
CN114380914A (en) 2022-04-22
US20180355056A1 (en) 2018-12-13
DK3313891T3 (en) 2026-06-15
JP2018526976A (en) 2018-09-20
PH12021551700A1 (en) 2022-11-07
LT3313891T (en) 2026-06-25
CL2017003261A1 (en) 2018-04-20
RU2020142517A (en) 2021-01-27
RU2018102798A3 (en) 2020-05-22
IL295859B1 (en) 2025-03-01
JP6698711B2 (en) 2020-05-27
MY185813A (en) 2021-06-10
SG10201913262RA (en) 2020-03-30
MA42243A (en) 2018-05-02
AU2019264514B2 (en) 2021-12-09
WO2016207858A1 (en) 2016-12-29
RU2018102798A (en) 2019-07-29
JP2022116069A (en) 2022-08-09
SI3313891T1 (en) 2026-07-31
RU2739946C2 (en) 2020-12-30
RS68174B1 (en) 2026-06-30
MX2017017144A (en) 2018-05-28
IL256376B (en) 2022-09-01
NZ777273A (en) 2025-05-30
EP3313891B1 (en) 2026-04-01
AU2025201731A1 (en) 2025-04-03
HK1250990A1 (en) 2019-01-18
EA036395B1 (en) 2020-11-05
CO2017013356A2 (en) 2018-03-20
JOP20160131B1 (en) 2022-03-14
CA2990764A1 (en) 2016-12-29
MX391310B (en) 2025-03-21
JP7587550B2 (en) 2024-11-20
EP3313891A1 (en) 2018-05-02
KR20190142448A (en) 2019-12-26
KR20180019733A (en) 2018-02-26
JP2024026169A (en) 2024-02-28
TWI743039B (en) 2021-10-21
TWI820482B (en) 2023-11-01
IL295859B2 (en) 2025-07-01
AU2021273615A1 (en) 2021-12-16
BR112017027778A2 (en) 2018-10-09
IL295859A (en) 2022-10-01
AU2016281957A1 (en) 2018-01-18
UY36751A (en) 2017-01-31
CU24498B1 (en) 2021-01-12
JP7823009B2 (en) 2026-03-03
JOP20200312A1 (en) 2020-12-03
PH12017502358A1 (en) 2018-06-25
CR20170600A (en) 2018-02-28
AU2021273615B2 (en) 2024-12-12
MY194928A (en) 2022-12-23
US10465011B2 (en) 2019-11-05
HRP20260688T1 (en) 2026-07-17
US20240067750A1 (en) 2024-02-29
AU2016281957B2 (en) 2019-08-15
MA42243B1 (en) 2026-05-26
CN107922505B (en) 2022-05-06
IL318883A (en) 2025-04-01
TW201722993A (en) 2017-07-01
US20170022292A1 (en) 2017-01-26
KR102059059B1 (en) 2020-02-12
PT3313891T (en) 2026-06-17
US20200115468A1 (en) 2020-04-16
TN2017000536A1 (en) 2019-04-12
ECSP18005520A (en) 2018-04-30
PL3313891T3 (en) 2026-07-27
EA201890145A1 (en) 2018-07-31
JP2026076151A (en) 2026-05-11
IL256376A (en) 2018-02-28
MX2022004072A (en) 2022-05-03
CN114773479A (en) 2022-07-22
CU20170169A7 (en) 2018-07-05
EP4763864A2 (en) 2026-06-24
CN107922505A (en) 2018-04-17
PE20180480A1 (en) 2018-03-07
FI3313891T3 (en) 2026-05-26
JP2020114216A (en) 2020-07-30
ES3073133T3 (en) 2026-07-08

Similar Documents

Publication Publication Date Title
EA202091590A1 (en) ANTIBODIES AGAINST PD-L1 AND THEIR APPLICATION OPTIONS
MY190771A (en) Anti-pd-l1 antibodies and uses thereof
JP2018508483A5 (en)
WO2015200806A3 (en) Humanized anti-tau antibodies
FI3459597T3 (en) Single domain antibody for ctla4 and derived protein thereof
RU2018133708A (en) BTLA SPECIFIC ANTIBODIES AND THEIR USE
JP2018527919A5 (en)
PE20221262A1 (en) THERAPEUTIC ANTIBODIES AND THEIR USES
JP2018501197A5 (en)
NZ602892A (en) Antibodies that bind human cd27 and uses thereof
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
JP2015503909A5 (en)
JP2016513664A5 (en)
RU2016100892A (en) ANTIBODIES AGAINST TWEAKR AND THEIR APPLICATION
WO2017060322A3 (en) Ptefb-inhibitor-adc
WO2019066435A3 (en) Anti-bcma antibody having high affinity for bcma and pharmaceutical composition for treatment of cancer, comprising same
EA201790816A1 (en) ANTIBODIES THAT ARE ASSOCIATED WITH CCR6 AND APPLICATION OPTIONS FOR THE INDICATED ANTIBODIES
RU2017114968A (en) BINDING MOLECULES, AND EXACTLY ANTIBODIES, ABLE TO CONTACT L1CAM (CD171)
WO2020257789A3 (en) Anti-tim-3 antibodies
JP2017529324A5 (en)
EA202190495A1 (en) ANTIBODIES AGAINST HUMAN PD-L1
JP2017511152A5 (en)
WO2015191590A3 (en) Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
WO2015191610A3 (en) Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
WO2015191602A3 (en) Combination therapies targeting tumor-associated stroma or tumor cells

Legal Events

Date Code Title Description
PSEA Patent sealed